Phase I trial of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1/2 and non-BRCA1/2 mutant cancers

Preclinical studies have demonstrated synergy between poly(ADP-ribose) polymerase (PARP) and phosphatidylinositol-3-kinase (PI3K)/AKT pathway inhibitors in BRCA1 and BRCA2 (BRCA1/2)-deficient and BRCA1/2-proficient tumors. We conducted an investigator-initiated phase I trial utilizing a prospective...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Discov
Main Authors: Yap, Timothy A., Kristeleit, Rebecca, Michalarea, Vasiliki, Pettitt, Stephen J., Lim, Joline S.J., Carreira, Suzanne, Roda, Desamparados, Miller, Rowan, Riisnaes, Ruth, Miranda, Susana, Figueiredo, Ines, Rodrigues, Daniel Nava, Ward, Sarah, Matthews, Ruth, Parmar, Mona, Turner, Alison, Tunariu, Nina, Chopra, Neha, Gevensleben, Heidrun, Turner, Nicholas C., Ruddle, Ruth, Raynaud, Florence I., Decordova, Shaun, Swales, Karen E., Finneran, Laura, Hall, Emma, Rugman, Paul, Lindemann, Justin P.O., Foxley, Andrew, Lord, Christopher J., Banerji, Udai, Plummer, Ruth, Basu, Bristi, Lopez, Juanita S., Drew, Yvette, de Bono, Johann S.
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7611385/
https://ncbi.nlm.nih.gov/pubmed/32532747
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-20-0163
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados